Use of genotyping for the optimization of treatment with biologics in chronic arthritis by looking for an association between certain alleles and response to treatment.
Chronic arthritis in children and in adults represent a public health problem in number and difficulty of treatment. 30% of patients are non-responders and / or relapse upon discontinuation of treatment. Some of these treatments are not always well tolerated, sometimes with infectious complications including tuberculosis limiting the use of biological therapies. This study will validate a battery of genetic markers to predict responders biotherapy, determine the prognosis of patients, these treatments are reserved for the most severe forms, and thus improve the care of patients.
Study Type
OBSERVATIONAL
Enrollment
379
Conservation at the end of the blood sample
Proportion of responsive patients with a given polymorphism (%)
Time frame: At the inclusion
Distribution of patients with a given biotherapy (%)
Time frame: At the inclusion
Distribution of patients presenting a given polymorphism (%)
Time frame: At the inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.